Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
Schatten H. Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies. Adv Exp Med Biol. 2018;1095:1–14.
CAS PubMed Article Google Scholar
Lorkowski J, Grzegorowska O, Kozień MS, Kotela I. Effects of breast and prostate cancer metastases on lumbar spine biomechanics: rapid in silico evaluation. Adv Exp Med Biol. 2018;1096:31–39.
CAS PubMed Article Google Scholar
Nguyen-Nielsen M, Borre M. Diagnostic and therapeutic strategies for prostate cancer. Semin Nucl Med. 2016;46:484–90.
Darwish OM, Raj GV. Management of biochemical recurrence after primary localized therapy for prostate cancer. Front Oncol. 2012;2:48.
PubMed PubMed Central Article Google Scholar
Cheng L, MacLennan GT, Bostwick DG. Urologic surgical pathology. 4rth ed. Philadelphia, PA: Elsevier; 2019.
Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2020;323:149–63.
PubMed PubMed Central Article Google Scholar
Myint ZW, Kunos CA. Bone fracture incidence after androgen deprivation therapy-investigational agents: results from cancer therapy evaluation program-sponsored early phase clinical trials 2006-2013. Front Oncol. 2020;10:1125.
PubMed PubMed Central Article Google Scholar
Cheung AS, Pattison D, Bretherton I, Hoermann R, Lim Joon D, Ho E, et al. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines. Andrology. 2013;1:583–9.
CAS PubMed Article Google Scholar
Curtis KK, Pruthi RK, Fonseca R, Gornet MK. Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer. Urology. 2007;70:811.e5–8.
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72.
CAS PubMed PubMed Central Article Google Scholar
Yan B, Ai Y, Sun Q, Ma Y, Cao Y, Wang J, et al. Membrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1. Mol Cell. 2021;81:355–369.e10.
CAS PubMed Article Google Scholar
Hambright WS, Fonseca RS, Chen L, Na R, Ran Q. Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol. 2017;12:8–17.
CAS PubMed PubMed Central Article Google Scholar
Li Y, Feng D, Wang Z, Zhao Y, Sun R, Tian D, et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death Differ. 2019;26:2284–99.
CAS PubMed PubMed Central Article Google Scholar
Wang M, Mao C, Ouyang L, Liu Y, Lai W, Liu N, et al. Correction to: Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. Cell Death Differ. 2020;27:1447.
Ma S, Henson ES, Chen Y, Gibson SB. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 2016;7:e2307.
CAS PubMed PubMed Central Article Google Scholar
Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 2021;81:1583–94.
CAS PubMed PubMed Central Article Google Scholar
Basuli D, Tesfay L, Deng Z, Paul B, Yamamoto Y, Ning G, et al. Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene. 2017;36:4089–99.
CAS PubMed PubMed Central Article Google Scholar
Bridges RJ, Natale NR, Patel SA. System xc- cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br J Pharm. 2012;165:20–34.
Pfeiffer R, Spindler B, Loffing J, Skelly PJ, Shoemaker CB, Verrey F. Functional heterodimeric amino acid transporters lacking cysteine residues involved in disulfide bond. FEBS Lett. 1998;439:157–62.
CAS PubMed Article Google Scholar
Liu T, Jiang L, Tavana O, Gu W. The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11. Cancer Res. 2019;79:1913–24.
CAS PubMed PubMed Central Article Google Scholar
Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 2014;3:e02523.
PubMed PubMed Central Article CAS Google Scholar
Patel D, Kharkar PS, Gandhi NS, Kaur E, Dutt S, Nandave M. Novel analogs of sulfasalazine as system xc- antiporter inhibitors: Insights from the molecular modeling studies. Drug Dev Res. 2019;80:758–77.
CAS PubMed Article Google Scholar
Genchi G, Sinicropi MS, Lauria G, Carocci A, Catalano A. The effects of cadmium toxicity. Int J Environ Res Public Health. 2020;17:3782.
CAS PubMed Central Article Google Scholar
Zhang Y, Guo S, Wang S, Li X, Hou D, Li H, et al. LncRNA OIP5-AS1 inhibits ferroptosis in prostate cancer with long-term cadmium exposure through miR-128-3p/SLC7A11 signaling. Ecotoxicol Environ Saf. 2021;220:112376.
CAS PubMed Article Google Scholar
Liu J, Zhang C, Hu W, Feng Z. Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett. 2015;356:197–203.
CAS PubMed Article Google Scholar
Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57–62.
CAS PubMed PubMed Central Article Google Scholar
Zhou X, Zou L, Chen W, Yang T, Luo J, Wu K, et al. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer. Pharm Res. 2021;164:105305.
Su LJ, Zhang JH, Gomez H, Murugan R, Hong X, Xu D, et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxid Med Cell Longev. 2019;2019:5080843.
PubMed PubMed Central Google Scholar
Cozza G, Rossetto M, Bosello-Travain V, Maiorino M, Roveri A, Toppo S, et al. Glutathione peroxidase 4-catalyzed reduction of lipid hydroperoxides in membranes: The polar head of membrane phospholipids binds the enzyme and addresses the fatty acid hydroperoxide group toward the redox center. Free Radic Biol Med. 2017;112:1–11.
CAS PubMed Article Google Scholar
He S, Zhang M, Ye Y, Zhuang J, Ma X, Song Y, et al. ChaC glutathione specific γ-glutamylcyclotransferase 1 inhibits cell viability and increases the sensitivity of prostate cancer cells to docetaxel by inducing endoplasmic reticulum stress and ferroptosis. Exp Ther Med. 2021;22:997.
CAS PubMed PubMed Central Article Google Scholar
Jelinek A, Heyder L, Daude M, Plessner M, Krippner S, Grosse R, et al. Mitochondrial rescue prevents glutathione peroxidase-dependent ferroptosis. Free Radic Biol Med. 2018;117:45–57.
CAS PubMed Article Google Scholar
Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317–31.
CAS PubMed PubMed Central Article Google Scholar
Xu P, Wang Y, Deng Z, Tan Z, Pei X. MicroRNA-15a promotes prostate cancer cell ferroptosis by inhibiting GPX4 expression. Oncol Lett. 2022;23:67.
CAS PubMed PubMed Central Article Google Scholar
Li R, Jia Z, Trush MA. Defining ROS in biology and medicine. React Oxyg Species. 2016;1:9–21.
He L, He T, Farrar S, Ji L, Liu T, Ma X. Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. Cell Physiol Biochem. 2017;44:532–53.
Zhao M, Wang Y, Li L, Liu S, Wang C, Yuan Y, et al. Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance. Theranostics. 2021;11:1845–63.
CAS PubMed PubMed Central Article Google Scholar
Arra M, Swarnkar G, Ke K, Otero JE, Ying J, Duan X, et al. LDHA-mediated ROS generation in chondrocytes is a potential therapeutic target for osteoarthritis. Nat Commun. 2020;11:3427.
留言 (0)